Influence of later exposure to perches and nests on flock level distribution of hens in an aviary system during lay.

Aviaries provide hens with many resources, but birds must develop motor and cognitive skills to use them properly. Introducing birds to aviaries at older ages has been reported to result in less use of perches, nests, and vertical space, which can reduce productivity and hen welfare. The objectives of this study were to examine (1) how enrichment influenced distribution of hens in the aviary during the day and (2) how enrichment influenced the distribution and roosting substrate of birds at night. Hy-Line W36 pullets were raised in floor pens before moving to laying aviaries (100 hens/aviary unit × 4 units/treatments). Control (CON) pullets were placed into aviaries at 17 wk of age (WOA). Floor (FLR) and enriched (ENR) pullets remained in floor pens until 25 WOA, and ENR birds were provided with perches and nests at 17 WOA. Birds were counted in tiers and litter areas of the aviary at morning, midday and evening at 36 and 54 WOA. Data were analyzed using generalized linear mixed models in R statistical software. At 36 WOA, ENR and CON birds occupied aviary areas at similar rates but differently from FLR birds. For example, in the morning 34% of CON hens and 30% of ENR hens occupied the highest tier compared to 15% of FLR hens (P < 0.01). At midday, 57% of CON and 57% of ENR birds were counted in litter compared with 77% of FLR birds (P < 0.01). In the evening, CON and ENR hens moved to the top tier of the aviary in greater numbers than FLR hens (22 and 17%, respectively, vs. 7%, P < 0.01). At 54 WOA, differences between FLR hens and CON/ENR hens were less pronounced, suggesting FLR hens were adapting to the aviary. Overall, we conclude that birds exposed to aviaries at 25 WOA can adapt to aviary systems, but take more time to do so than birds exposed to aviaries or vertical enrichment at 17 WOA.

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.

BACKGROUND: We report the first results of a randomized trial assessing a new oral aminobisphosphonate, ibandronate, in patients with bone metastases from breast cancer. PATIENTS AND METHODS: Patients (n = 435) received placebo, or oral ibandronate 20 mg or 50 mg once-daily for 96 weeks. The primary efficacy measure was the number of 12-week periods with new bone complications [skeletal morbidity period rate (SMPR)]. Multivariate Poisson regression analysis assessed the relative risk reduction of skeletal-related events. Secondary efficacy analyses included bone pain and analgesic use. Adverse events were monitored. RESULTS: SMPR was significantly reduced with oral ibandronate [placebo 1.2, 20 mg group 0.97 (P = 0.024), 50 mg group 0.98 (P = 0.037)]. Ibandronate 50 mg significantly reduced the need for radiotherapy (P = 0.005 versus placebo). The relative risk of skeletal events was reduced by 38% (20 mg dose) and 39% (50 mg dose) versus placebo (P = 0.009 and P = 0.005). The tolerability profile of ibandronate was similar to placebo. CONCLUSIONS: Oral ibandronate is an effective and well-tolerated treatment for metastatic bone disease. The 50 mg dose is being further evaluated in clinical trials, and this dose was recently approved in the European Union for the prevention of skeletal events in patients with breast cancer and bone metastases.

Synthesis-secretion coupling of insulin: effect of aging.

Synthesis-secretion coupling of insulin was measured in four age groups of perfused pancreases taken from Sprague-Dawley rats ranging in age from 2-12 months. The effect of long term (6 h) near-maximal glucose stimulation (300 mg/dl) on both insulin secretion and net insulinogenesis demonstrated an age-related increase in both parameters. Net insulinogenesis as well as total insulin secretion increased linearly as a function of aging. Compared to that in 2-month-old rats, total net insulin synthesis was more than 3-fold greater in 12-month-old rats, slightly less than 3-fold greater in 8-month-old rats, and twice as much in 4-month-old rats. Compared to that in 2-month-old rats, total glucose-stimulated insulin secretion was 3-fold greater in 12-month-old rats, approximately 2.2-fold greater in 8-month-old rats, and about 1.7-fold greater in 4-month-old rats. A shorter term (90 min) glucose stimulation at 150 mg/dl produced an age-related increase in insulin secretion which was relatively comparable to the higher glucose stimulus. Of equal importance is that fact that pancreases from the older rats exhibited the same degree of secretory responsiveness to changing glucose levels as did pancreases from the younger rats. Regardless of age, first phase insulin secretion was approximately twice as much in response to the higher glucose level as to the lower. Similarly, second phase insulin secretion was almost 3 times greater regardless of age. When normalized and reported in terms of insulin content, total insulin secretion was no different as a function of aging during the first 1 h of glucose stimulation (i.e. the first two phases of secretion), but it was significantly elevated in the third secretory phase (2-6 h) by the older rat groups. Total 6-h net insulinogenesis was also greater in the older rat groups. When normalized and reported in terms of total body weight, both insulin synthesis and total insulin secretion became comparable and showed no specific age-related difference. Thus, there is no indication that aging results in an uncoupling of relatively long term (6-h) insulin synthesis-secretion, since both glucose-induced responses parallel one another as a function of aging. Furthermore, reporting insulin secretion and synthesis on the basis of body weight, rather than age, totally normalizes synthesis-secretion coupling of insulin.